Sanofi backed KT501 for up to $1.23bn. FDA has now opened the U.S. trial path
Kali Therapeutics has received FDA IND clearance for KT501, a CD19xBCMAxCD3 trispecific T-cell engager designed to produce deep B-cell and plasma-cell depletion in autoimmune disease.